Keywords: AstraZeneca, Prosidion, Diabetes assets, Dynavax, TLR-9 agonist, Asthma

AstraZeneca takes option on Prosidion diabetes assets; advances asthma drug

Article | 22 December 2011

Print This

Looking to expand its R&D pipeline in the face of several recent product failures and facing a “ ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in